{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Anti-PSMACD28_Bispecific_Antibody_REGN5678",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of anti-PSMA/CD28 bispecific antibody REGN5678, this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.",
    "fdaUniiCode": "M355PGI1TG",
    "identifier": "C162936",
    "preferredName": "Anti-PSMA/CD28 Bispecific Antibody REGN5678",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C176017",
      "C28227"
    ],
    "synonyms": [
      "Anti-PSMA/Anti-CD28 Bispecific Antibody REGN5678",
      "Anti-PSMA/CD28 Bispecific Antibody REGN5678",
      "Anti-PSMAxCD28 Antibody REGN5678",
      "REGN 5678",
      "REGN-5678",
      "REGN5678"
    ]
  }
}